SCHEMBL5558327

SCHEMBL5558327

NC1CC2CC1CC2O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29483911 1.00
SCHEMBL23498787 1.00
Hydrochloric Acid SCHEMBL30340427 0.97
SCHEMBL1604317 0.80
SCHEMBL22613944 0.80
SCHEMBL584025 0.80
SCHEMBL820453 0.80
SCHEMBL21098299 0.80 CYP2C9 (0.33)
SCHEMBL2836928 0.80
SCHEMBL14441066 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100221809-A1 Compositions and Methods for the Isolation of Biologically Active Proteins THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2010-09-02 US disclosed
US-20100221809-A1 Compositions and Methods for the Isolation of Biologically Active Proteins THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2010-09-02 US disclosed
WO-2007130353-A2 PHASE 2 INDUCERS, PPAR-ALPHA AGONISTS AND RELATED SIGNALLING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS JOHNS HOPKINS UNIVERSITY (US) 2007-11-15 WO disclosed
US-20070197538-A1 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-08-23 US disclosed